Shanghai Haohai Biological Technology Co., Ltd. (Haohai Biotech) disclosed that it bought back 36,000 H-shares on 15 May 2026 via the Hong Kong Stock Exchange at prices ranging from HKD 21.78 to HKD 22.04 per share, spending HKD 0.79 million in aggregate. The repurchased shares are designated for cancellation and remain in treasury pending that process.

• Issued share capital unchanged: As of 15 May 2026, Haohai Biotech’s issued share capital (excluding treasury shares) stood at 226.13 million, comprising 190.20 million A-shares and 35.93 million H-shares.

• Cumulative buy-backs awaiting cancellation: Since 23 March 2026, the company has repurchased 1.15 million H-shares at prices between HKD 21.55 and HKD 22.87, all of which remain uncancelled.

• Repurchase mandate utilisation: Under the mandate granted on 10 June 2025 allowing up to 3.91 million H-share buy-backs, Haohai Biotech has repurchased 3.75 million shares to date, equivalent to 9.58 % of the outstanding shares at the time of authorisation.

• Moratorium on new issues: In line with Hong Kong listing rules, the company is restricted from issuing new shares or selling treasury shares until 14 June 2026.

No changes were recorded in the company’s A-share capital during the period under review, and the total of 3.85 million A-shares held in treasury remains unchanged.